BioTechnologyNews.net
April 11, 2008 by admin
Filed under Media Reports, Media Reports 2008
| Monoclonal asthma trials kick off in Australia THE value of Australia as a clinical research site has again been reinforced, with private US biotech company KaloBios Pharmaceuticals launching a Phase 1/2 trial in Australia for the company’s engineered monoclonal antibody in persistent asthma. |
View online article ยป
For a licensed copy [CAL] of this article please email us at: team{at}onlinemediarooms.com |
